Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients

British Journal of Rheumatology

Volumn 37, Issue 9, 1998, Pages 937-945

  Hawkey, C ^h   Kahan, A ^a   Steinbruck K ^h   Alegre, C ^b   Baumelou, E ^c   Begaud B ^d   Dequeker, J ^e   Isomaki H ^f   Littlejohn, G ^h   Mau, J ^g   Papazoglou, S ^h  

^a Hôpital Cochin ^*  (France)

^b Hosp de Enferm Reumáticas   (Spain)

^c FOCH HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h NONE

Author keywords

COX 2; Large scale clinical trial; Meloxicam; NSAID; Osteoarthritis

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMACH PERFORATION; STOMACH ULCER; VOMITING;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; OSTEOARTHRITIS; PATIENT DROPOUTS; PEPTIC ULCER; PROSPECTIVE STUDIES; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0031685519     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Larkai EN, Smith JL, Lidsky MD et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62.
2. Giercksky KE, Huseby G, Rugstad HE et al. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol 1989;24:3-8.
3. Fries J. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18:6-10.
4. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
5. Brogden RN, Heel RC, Speight TM, Avery GS. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984;28:292-323.
6. Bateman N. NSAIDs: time to re-evaluate gut toxicity. Lancet 1994;343:1051-2.
7. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature (New Biol) 1971;231:232-5.
8. Wong WYL, Richards JS. Evidence for two antigenically distinct molecular weight variants of prostaglandin H synthase in the rat ovary. Mol Endocrinol 1991;5: 1269-79.
9. Xie W, Chipman JG, Robertson DL, Erikson RC, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by RNA splicing. Proc Natl Acad Sci USA 1991;88:2692-8.
10. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclo-oxygenase enzyme. Proc Natl Acad Sci USA 1992;89: 3917-21.
11. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271-3.
12. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-54.
13. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
14. Lee SH, Soyoola E, Chanmugam P et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-8.
15. Vane JR. Towards a better aspirin. Nature 1994; 367:215-6.
16. Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. In vitro findings - part I. Biochem Pharmacol 1996; 51:21-8.
17. Churchill L, Graham AG, Shih C-K et al. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology 1996;4:125-35.
18. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, eds. Improved non-steroid anti-inflammatory drugs - COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic, 1996:103-19.
19. Patrignani P, Panara MR, Dsantini G et al. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isoenzymes in vitro and ex vivo in man. Prostaglandins Leukotrienes Essential Fatty Acids 1996;55(suppl. 1):98 (Abstract P115).
20. Stichtenoth DO, Guzzki FM, Wagner B, Tsikas D, Frölich JC. Meloxicam, a new NSAID, is cyclo-oxygenase-1 sparing in humans in vivo. J Invest Med 1996;44:297A.
21. Distel M, Mueller C, Bluhmki E, Fries S. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35:68-77.
22. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double blind comparison with diclofenac sodium. Br J Rheumatol 1996;35:39-43.
23. Willkens RF. Worldwide clinical safety experience with diclofenac. Semin Arthritis Rheum 1985;15:105-10.
24. Bellamy N, Carette S, Ford PM et al. Osteoarthritis antirheumatic drug trials III. Setting the delta for clinical trials - results of a consensus development (Delphi) exercise. J Rheumatol 1992;19:451-7.
25. Henry D, Lim LL-Y, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996;312:1563-6.
26. Langman MJS, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343: 1075-8.
27. Hawkey CJ, Nottingham GI Trials Service for the International SELECT Study Group. Low gastrointestinal toxicity of meloxicam, a preferential inhibitor of the inducible cyclooxygenäse (COX-2) enzyme compared to piroxicam. Gut 1997;41:A7.
28. Chalmers TC, Berrier J, Hewitt P et al. Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 1988;2:9-26.
29. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-9.
30. Garcia Rodriguez LA, Walker AM, Perez Gutthann S. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992;3:337-42.
31. Schattenkirchner M. Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug. Expert Opin Invest Drugs 1997;6:321-34.
32. Amundsen T, Bleken L, Børkje B et al. Variation in response to naproxen and diclofenac in patients with osteoarthritis. Curr Ther Res 1983;33:793-801.
33. Boardman PL, Burke MJ, Camp AV et al. Treatment of osteoarthritis with piroxicam. Eur J Rheumatol Inflamm 1983;6:73-83.
34. Heynen G. A double blind placebo controlled trial of piroxicam in 591 patients with osteoarthritis. In: The disease process: focus on piroxicam. Royal Society of Medicine International Congress and Symposium Series No. 67, 1984:19-22.
35. Germain BF. A placebo controlled study of diclofenac sodium for the treatment of osteoarthritis of the hip or knee. Curr Ther Res 1985;37:259-68.